| Makenna Marie Sisson, MCD, CFY-SLP | |
|
6815 Isaacs Orchard Rd Ste D, Springdale, AR 72762-6285 | |
| (479) 856-6400 | |
| Not Available |
| Full Name | Makenna Marie Sisson |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 6815 Isaacs Orchard Rd Ste D, Springdale, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013660737 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 201712 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Makenna Marie Sisson, MCD, CFY-SLP 6815 Isaacs Orchard Rd Ste D, Springdale, AR 72762-6285 Ph: (479) 856-6400 | Makenna Marie Sisson, MCD, CFY-SLP 6815 Isaacs Orchard Rd Ste D, Springdale, AR 72762-6285 Ph: (479) 856-6400 |
News Archive
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application for SPRYCEL (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Stormont-Vail HealthCare and Mayo Clinic officials announced today that the Topeka-based health system has become a member of the Mayo Clinic Care Network, a national network of like-minded organizations that share a commitment to better serving patients and families.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has been awarded a contract by the Defense Advanced Research Projects Agency (DARPA), to use its proprietary somatic hypermutation (SHM) technology platform to generate novel high affinity thermally stable antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats.
Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.
› Verified 4 days ago
Lauren Mariah Dixon, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 956 Mathias Dr, Springdale, AR 72762 Phone: 479-419-9911 | |
Christa Griffith, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2210 Main Dr, Springdale, AR 72762 Phone: 479-856-6397 | |
Bailey Aleece Norton, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2070 Mckenzie Rd Ste C, Springdale, AR 72762 Phone: 479-750-7778 | |
Kathryn Michelle Cochran, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3917 S Old Missouri Rd, Springdale, AR 72764 Phone: 479-872-1800 Fax: 479-872-4654 | |
Ms. Sarah Elizabeth Dennis, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 105 S Blair St, Springdale, AR 72764 Phone: 479-200-6795 | |
Tara Ray Wright, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 105 S Blair St, Springdale, AR 72764 Phone: 479-259-2339 Fax: 479-751-4000 |